August 2012 in “Journal of Evidence-Based Medicine” The issue discussed China's research contributions, systematic review improvements, and featured various medical studies and trials.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
September 2023 in “Journal of the American Academy of Dermatology”
12 citations
,
September 2002 in “Epilepsia” Monitoring new epilepsy drugs after they're sold is crucial to find rare and long-term side effects that initial tests might miss.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
January 2026 in “Figshare” January 2026 in “Figshare” 22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
The study aims to find the best PRP dose for treating moderate carpal tunnel syndrome.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
5 citations
,
May 2018 in “Drug Safety” Using electronic health records can help identify drug side effects but has some limitations.
8 citations
,
April 1979 in “Journal of Cutaneous Pathology” Giant cells found in some male pattern baldness cases may help diagnose it and suggest hair is mistakenly seen as foreign by the body.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
July 2003 in “Pediatrics in review” In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.
February 1998 in “American Journal of Health-System Pharmacy” Yale-New Haven Hospital won a top award for greatly improving asthma care and reducing related hospital visits and costs.
1 citations
,
March 2024 in “Skin health and disease” Vibration assisted analgesia reduces pain during corticosteroid therapy for alopecia.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
The trial aims to understand how obesity and lifestyle affect circadian rhythms in people with schizophrenia and bipolar disorder.
1 citations
,
April 2009 in “Journal of Intellectual Property Law & Practice” UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
December 2025 in “Frontiers in Nutrition” The albumin change rate helps predict treatment success in AIDS-related non-Hodgkin lymphoma.
December 2012 in “http://isrctn.org/>” 2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
September 2023 in “Journal of the American Academy of Dermatology” Hispanic and Black patients are underrepresented in alopecia areata clinical trials.
62 citations
,
March 2008 in “American Journal of Human Genetics” Hair loss gene found on chromosome 3q26.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.